Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59


Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo.

Su YL, Swiderski P, Marcucci G, Kortylewski M.

Methods Mol Biol. 2019;1974:141-150. doi: 10.1007/978-1-4939-9220-1_10.


Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.

Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M.

Int J Mol Sci. 2019 Apr 13;20(8). pii: E1831. doi: 10.3390/ijms20081831.


STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.

Moreira D, Adamus T, Zhao X, Su YL, Zhang Z, White SV, Swiderski P, Lu X, DePinho RA, Pal SK, Kortylewski M.

Clin Cancer Res. 2018 Dec 1;24(23):5948-5962. doi: 10.1158/1078-0432.CCR-18-1277. Epub 2018 Oct 18.


SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, Du J, Wang H, Wu X, Zhang L, Yu X, Lin A, McDonald T, Zhao D, Wu H, Hua WK, Zhang B, Feng L, Tohyama K, Bhatia R, Oberdoerffer P, Chung YJ, Aplan PD, Boultwood J, Pellagatti A, Khaled S, Kortylewski M, Pichiorri F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L.

Cell Stem Cell. 2018 Sep 6;23(3):355-369.e9. doi: 10.1016/j.stem.2018.07.018. Epub 2018 Aug 23.


STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.

Su YL, Banerjee S, White SV, Kortylewski M.

Int J Mol Sci. 2018 Jun 19;19(6). pii: E1803. doi: 10.3390/ijms19061803. Review.


SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.

Skrzypek K, Kusienicka A, Trzyna E, Szewczyk B, Ulman A, Konieczny P, Adamus T, Badyra B, Kortylewski M, Majka M.

Cell Death Dis. 2018 May 29;9(6):643. doi: 10.1038/s41419-018-0693-8.


The revival of CpG oligonucleotide-based cancer immunotherapies.

Adamus T, Kortylewski M.

Contemp Oncol (Pozn). 2018 Mar;22(1A):56-60. doi: 10.5114/wo.2018.73887. Epub 2018 Mar 5. Review.


Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients.

Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, Vora L, Maghami E, Kortylewski M.

Oncotarget. 2018 Feb 2;9(13):11279-11290. doi: 10.18632/oncotarget.24397. eCollection 2018 Feb 16.


Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.


B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

Zhao X, Zhang Z, Moreira D, Su YL, Won H, Adamus T, Dong Z, Liang Y, Yin HH, Swiderski P, Pillai RK, Kwak L, Forman S, Kortylewski M.

Mol Ther. 2018 Mar 7;26(3):695-707. doi: 10.1016/j.ymthe.2018.01.007. Epub 2018 Jan 17.


Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.


Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.

Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19.


Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.

Kozlowska AK, Florczak A, Smialek M, Dondajewska E, Mackiewicz A, Kortylewski M, Dams-Kozlowska H.

Acta Biomater. 2017 Sep 1;59:221-233. doi: 10.1016/j.actbio.2017.07.014. Epub 2017 Jul 8.


TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.

Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, D'Apuzzo M, Pal S, Kortylewski M.

J Leukoc Biol. 2017 Aug;102(2):423-436. doi: 10.1189/jlb.3MA1016-451RR. Epub 2017 May 22.


Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Kortylewski M, Moreira D.

Cancer Immunol Immunother. 2017 Aug;66(8):979-988. doi: 10.1007/s00262-017-1966-2. Epub 2017 Feb 18. Review.


STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.

Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M, Kline J.

Cell Rep. 2016 Jun 14;15(11):2357-66. doi: 10.1016/j.celrep.2016.05.023. Epub 2016 Jun 2.


Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer.

Pal SK, Kortylewski M.

Oncoimmunology. 2015 Aug 24;5(2):e1078060. eCollection 2016 Feb.


Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, Cai Q, Swiderski P, Kuo YH, Forman S, Marcucci G, Kortylewski M.

Blood. 2016 Mar 31;127(13):1687-700. doi: 10.1182/blood-2015-08-665604. Epub 2016 Jan 21.


TLR9-Targeted SiRNA Delivery In Vivo.

Hossain DM, Moreira D, Zhang Q, Nechaev S, Swiderski P, Kortylewski M.

Methods Mol Biol. 2016;1364:183-96. doi: 10.1007/978-1-4939-3112-5_15.


Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors.

Pal SK, Li SM, Wu X, Qin H, Kortylewski M, Hsu J, Carmichael C, Frankel P.

Clin Cancer Res. 2015 Dec 1;21(23):5286-93. doi: 10.1158/1078-0432.CCR-15-0724. Epub 2015 Jul 7.

Supplemental Content

Loading ...
Support Center